Radius Health Inc. | |
Stock Exchange | Frankfurt Stock Exchange |
EPS |
- |
Market Cap |
- |
Shares Outstanding |
45.48 M |
Public Float |
33.48 M |
Radius Health Inc. | |
Stock Exchange | NASDAQ Stock Market |
EPS |
$4.45 |
Market Cap |
$1.14 B |
Shares Outstanding |
46.11 M |
Public Float |
45.29 M |
Address |
950 Winter Street Waltham Massachusetts 02451 United States |
Employees | - |
Website | http://www.radiuspharm.com |
Updated | 07/08/2019 |
Radius Health, Inc. is a biopharmaceutical company, which engages in developing and commercializing endocrine therapeutics in the areas of osteoporosis and oncology. The firm's lead product, Abaloparatide-SC, reduces fracture risk in postmenopausal women with osteoporosis. Its pipeline also includes abaloparatide transdermal patch for potential use in osteoporosis and RAD1901 for potential use in hormone-driven, or hormone-resistant, metastatic breast cancer, and vasomotor symptoms in postmenopausal women. |